Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
0.55
Industry P/E
--
Debt to Equity
--
ROE
-0.64 %
ROCE
-114.92 %
Div. Yield
0 %
Book Value
11.48
EPS
-14.2
CFO
$-105.58 Mln
EBITDA
$-143.95 Mln
Net Profit
$-165.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Quantum BioPharma
| 71.20 | 28.83 | 90.33 | -80.62 | -54.81 | -49.63 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Quantum BioPharma
| 16.69 | -22.75 | -34.62 | -71.26 | -87.37 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 3.15 | 585.93 | -- | -68.76 | |
| 5.10 | 1,662.81 | -- | 4 | |
| 1.77 | 677.08 | 16.09 | 3.8 | |
| 2.52 | 118.17 | -- | 36 |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug... candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada. Address: 55 University Ave., Toronto, ON, Canada, M5J 2H7 Read more
Founder, CEO, President & Executive Co-Chairman
Mr. Zeeshan Saeed
Founder, CEO, President & Executive Co-Chairman
Mr. Zeeshan Saeed
Headquarters
--
Website
--
Our rating system has guided millions of investors in the past 20 years.
The share price of Quantum BioPharma Ltd is $6.30 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Quantum BioPharma Ltd has given a return of -54.81% in the last 3 years.
Since, TTM earnings of Quantum BioPharma Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Quantum BioPharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Quantum BioPharma Ltd.
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada. Address: 55 University Ave., Toronto, ON, Canada, M5J 2H7
The CEO & director of Mr. Zeeshan Saeed. is Quantum BioPharma Ltd, and CFO & Sr. VP is Mr. Zeeshan Saeed.
There is no promoter pledging in Quantum BioPharma Ltd.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
279
|
|
|
75
|
|
|
69
|
|
|
7
|
| Quantum BioPharma Ltd | Ratios |
|---|---|
|
Return on equity(%)
|
-114.92
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Quantum BioPharma Ltd was No Profit.
$0.06
(
